(NASDAQ: IMCR) Immunocore Holdings's forecast annual revenue growth rate of 13.93% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.47%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.24%.
Immunocore Holdings's revenue in 2025 is $333,581,000.On average, 5 Wall Street analysts forecast IMCR's revenue for 2025 to be $18,989,057,706, with the lowest IMCR revenue forecast at $18,473,711,111, and the highest IMCR revenue forecast at $19,450,453,405. On average, 5 Wall Street analysts forecast IMCR's revenue for 2026 to be $20,774,460,637, with the lowest IMCR revenue forecast at $19,028,491,089, and the highest IMCR revenue forecast at $22,439,353,140.
In 2027, IMCR is forecast to generate $25,848,858,884 in revenue, with the lowest revenue forecast at $24,093,043,549 and the highest revenue forecast at $29,115,399,776.